Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4. 

On Wednesday, $AKBA closed at $1.04, indicating a potential upside of $2.96 or 284% based on Piper Sandler's view.

MDxHealth SA (Nasdaq: MDXH), a molecular diagnostics company, was initiated with an Outperform rating by TD Cowen, who set the price target at $7. 

With $MDXH closing price of $3.64 on Wednesday, this suggests a potential upside of $3.36 or 92% based on TD Cowen's perspective.

Avis Budget Group, Inc. (Nasdaq: CAR), a car rental company, received an upgrade from Hold to Buy by Deutsche Bank, along with a raised price target from $239 to $263. 

On Wednesday, $CAR closed at $167.79, indicating a potential upside of $95.21 or 57% according to Deutsche Bank's view.

argenx SE (Nasdaq: ARGX), a biotechnology company, was initiated with a Buy rating and a price target of $480 by UBS. 

With $ARGX closing price of $388.70 on Wednesday, this initiation suggests a potential upside of $91.30 or 23% based on UBS's analysis.

Five9, Inc. (Nasdaq: FIVN), a cloud contact center software provider, was initiated with a Buy rating by Mizuho, who set the price target at $100. 

On Wednesday, $FIVN closed at $66.11, implying a potential upside of $33.89 or 51% according to Mizuho's view.

Inventiva S.A. (Nasdaq: IVA), a biopharmaceutical company, was initiated with a Buy rating and a price target of $11 by ROTH MKM. 

With $IVA closing price of $3.94 on Wednesday, this initiation indicates a potential upside of $7.06 or 179% based on ROTH MKM's analysis.

It's important to note that these potential upsides are based on the views of the respective brokerage firms, investment firms, or analysts. Investors should consider conducting their own research and analysis before making any investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)